RxDoctor Payments Data

Gregory Grant, MD

Family Medicine · Shawnee, OKNPI 1609918234

Payments from drug & device makers

$1,723in general payments, 2019–2025

Across 66 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$870
  • AstraZeneca$431
  • Novo Nordisk$169
  • Astellas Pharma US Inc$57
  • Lilly USA, LLC$54
  • Dexcom, Inc.$46
  • plus $97 from 4 others

What the payments were for

  • Food & beverage$1,70999%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,723 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$99,475
Medicare patients
338
Services billed
2,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide162$224,523
JardianceEmpagliflozin102$115,007
EliquisApixaban136$107,295
MounjaroTirzepatide73$93,777
EnbrelEtanercept11$84,778
Synjardy XrEmpagliflozin/Metformin Hcl56$65,421
RybelsusSemaglutide31$56,992
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$54,138
TrulicityDulaglutide44$52,428
MyrbetriqMirabegron50$39,568
XareltoRivaroxaban41$31,080
LinzessLinaclotide27$28,210
Tresiba Flextouch U-100Insulin Degludec39$27,056
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$24,756
Buprenorphine104$20,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$169$281,514193 claims
Lilly USA, LLCMounjaro, Trulicity$54$146,205117 claims
PfizerEliquis$18$107,295136 claims
AbbVieLinzess, Namzaric, Vraylar, Synthroid$870$67,08999 claims
Astellas Pharma US IncMyrbetriq$57$39,56850 claims
Johnson & JohnsonXarelto$17$31,08041 claims
AstraZenecaBreztri Aerosphere, Brilinta$431$30,75747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Shawnee

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →